• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.

作者信息

Gao Xiaoshuai, Chen Guo, Wei Xin

机构信息

Department of Urology, Institute of Urology, Laboratory of Reconstructive Urology, West China Hospital, Sichuan University, Chengdu, China.

Department of Urology, Institute of Urology, Laboratory of Reconstructive Urology, West China Hospital, Sichuan University, Chengdu, China; Department of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.

出版信息

Eur Urol. 2021 Dec;80(6):e143-e144. doi: 10.1016/j.eururo.2021.09.012. Epub 2021 Sep 27.

DOI:10.1016/j.eururo.2021.09.012
PMID:34593263
Abstract
摘要

相似文献

1
Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.回复：森庆一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔法埃伊等。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》2021年；79：783 - 92。
Eur Urol. 2021 Dec;80(6):e143-e144. doi: 10.1016/j.eururo.2021.09.012. Epub 2021 Sep 27.
2
Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?回复：森庆一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔菲等人。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.10.006：免疫检查点抑制剂的临床活性：宿主是答案吗？
Eur Urol. 2021 Apr;79(4):e112. doi: 10.1016/j.eururo.2021.01.013. Epub 2021 Jan 29.
3
Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.回复高晓帅、陈果和魏鑫致编辑的信，信的内容涉及：森英一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔法埃伊等人。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》2021年；79卷：783 - 92页
Eur Urol. 2021 Dec;80(6):e145-e146. doi: 10.1016/j.eururo.2021.09.013. Epub 2021 Sep 25.
4
Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?回复约翰娜·诺埃尔、奥利维耶·于利亚尔和弗朗索瓦·戈德瓦塞尔致编辑的信，信的内容涉及：森英一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔菲等人的《程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析》。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.10.006。免疫检查点抑制剂的临床活性：宿主是答案吗？
Eur Urol. 2021 Apr;79(4):e113-e114. doi: 10.1016/j.eururo.2021.01.012. Epub 2021 Jan 21.
5
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.程序性死亡配体 1 预测转移性肾细胞癌患者接受免疫检查点抑制剂治疗的价值：系统评价和荟萃分析。
Eur Urol. 2021 Jun;79(6):783-792. doi: 10.1016/j.eururo.2020.10.006. Epub 2020 Nov 7.
6
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.程序性细胞死亡蛋白 1 与程序性细胞死亡配体 1 抑制剂在转移性肾细胞癌中的肿瘤学和毒性结局差异：系统评价和荟萃分析。
Cancer Treat Rev. 2021 Sep;99:102242. doi: 10.1016/j.ctrv.2021.102242. Epub 2021 Jun 12.
7
Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.回复：齐亚德·巴库尼、塔拉勒·埃尔·扎里夫、沙恩·杜达尼等人。免疫检查点抑制剂或靶向治疗的转移性肾细胞癌的 upfront 减瘤性肾切除术：来自国际转移性肾细胞癌数据库联盟的一项观察性研究。《欧洲泌尿外科杂志》2023 年；83 卷：145 - 151 页。
Eur Urol. 2023 Sep;84(3):e75. doi: 10.1016/j.eururo.2023.04.040. Epub 2023 Jun 1.
8
Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?免疫检查点抑制剂在转移性透明细胞肾细胞癌中的应用：PD-L1表达是否有用？
Eur Urol. 2021 Jun;79(6):793-795. doi: 10.1016/j.eururo.2021.02.040. Epub 2021 Mar 26.
9
Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.回复：丹尼尔·D·夏皮罗、何塞·A·卡拉姆、洛根·曾普等。免疫检查点抑制剂治疗后减瘤性肾切除术安全且有助于延长无治疗间期。《欧洲泌尿外科开放科学》2023年；50卷：43 - 6页
Eur Urol. 2023 Aug;84(2):e53-e54. doi: 10.1016/j.eururo.2023.03.042. Epub 2023 May 5.
10
Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.接受 PD-1/PD-L1 抑制剂治疗的尿路上皮癌或肾细胞癌患者的超进展性疾病。
Clin Genitourin Cancer. 2020 Apr;18(2):e122-e133. doi: 10.1016/j.clgc.2019.09.009. Epub 2019 Sep 26.